Unknown

Dataset Information

A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China.


ABSTRACT:

Aim

To investigate the use of docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in real-world clinical practice in China.

Methods

This single-arm, prospective, observational study was conducted at 32 study centers in China and included male patients aged ≥18 years with histologically confirmed prostate cancer who received ≥1 dose of docetaxel following failure of hormonal therapy (disease progression with serum testosterone <50 ng/dL). The primary aim was to investigate patterns of docetaxel treatment.

Results

Overall 403 patients were included between August 2011 and June 2016; patients initiated docetaxel after failure of first- (42.2% [170]), second- (31.0% [125]) and ≥third-line (12.7% [51]) hormonal therapy, estramustine (11.4

SUBMITTER: He D 

PROVIDER: S-EPMC6850484 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature